High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience.

Autor: Nasr LF; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zoghbi M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lazcano R; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nakazawa M; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Bishop AJ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Farooqi A; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mitra D; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Guadagnolo BA; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Benjamin R; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Patel S; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ravi V; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Araujo DM; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Livingston A; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zarzour MA; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Conley AP; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ratan R; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Somaiah N; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lazar AJ; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Roland C; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Keung EZ; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nassif Haddad EF; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 May 01; Vol. 16 (9). Date of Electronic Publication: 2024 May 01.
DOI: 10.3390/cancers16091763
Abstrakt: Background: Undifferentiated pleomorphic sarcomas (UPSs) are amongst the most common subtypes of soft-tissue sarcomas. Few real-world data on the use of immune checkpoint blockade (ICB) in UPS patients and other high-grade pleomorphic STS patients are available.
Purpose: The purpose of our study is to describe the efficacy and toxicity of ICB in patients with advanced UPSs and other high-grade pleomorphic sarcomas treated at our institution.
Methods: This is a retrospective, observational study of all patients with metastatic high-grade pleomorphic sarcomas treated with FDA-approved ICB at MD Anderson Cancer Center between 1 January 2015 and 1 January 2023. Patients included in trials for which results are not yet published were excluded.
Results: Thirty-six patients with advanced/metastatic pleomorphic sarcomas were included. The median age was 52 years. A total of 26 patients (72%) had UPSs and 10 patients (28%) had other high-grade pleomorphic sarcomas. The median follow-up time was 8.8 months. The median PFS was 2.9 months. The 3-month PFS and 6-month PFS were 46% and 32%, respectively. The median OS was 12.9 months. The 12-month OS and 24-month OS were 53% and 29%, respectively. The best response, previous RT, and type of ICB treatment were significantly and independently associated with shorter PFS ( p = 0.0012, p = 0.0019 and p = 0.036, respectively). No new safety signal was identified, and the toxicity was overall manageable with no toxic deaths and only four patients (11%) stopping treatment due to toxicity.
Conclusions: Real-world retrospective data are consistent with the published literature, with a promising 6-month PFS of 32%. Partial or stable responders to ICB treatment have significantly improved PFS compared to progressors.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje